This article is more than 5 years old. Information may no longer be current.

TLC, Vascular Sciences to jointly market AMD treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TLC Vision Corp. has entered into a joint venture with Vascular Sciences Corp. to commercialize the rheopheresis blood filtration process for the treatment of age-related macular degeneration in the United States, Canada and Mexico. The joint venture, OccuLogix, hopes to have its first Canadian commercial facility open in Canada by the end of this year.

Rheopheresis filters from the blood certain high molecular weight plasma proteins and lipoproteins that are believed to contribute to the development of AMD. The process is currently undergoing a pivotal study in the United States. The companies expect to submit data to U.S. regulators some time in late 2003 or early 2004.